The Ocular Hypertension
Treatment Study (OHTS)
was designed to determine if
using eyedrop medicines to lower eye pressure prevents or delays
glaucoma in people with high eye pressure. The medicines used
are commercially available FDA-approved medicines proven to
be effective in the treatment of high eye pressure.
This study is funded primarily
by the National Eye Institute, Department of Health and Human
Services of the federal government. Funding includes the costs
of care for study participants at 22 clinics and evaluation
of study information at 4 resource centers.
Enrollment of study participants
started in 1994 and ended in 1997. 1,636 individuals with
increased intraocular pressure and no evidence of glaucoma were
randomly assigned to receive eyedrop medication or no medication
An independent Data and Safety
Monitoring Committee appointed by the National Eye Institute
monitored the safety and efficacy and approved protocol changes.
visit the OHTS Risk website for information about the Glaucoma
5-Year Risk Estimator: